Molecular profiling studies, particularly from The Cancer Genome Atlas (TCGA), have identified key genetic alterations underlying GBM pathogenesis, including EGFR amplification, PTEN deletion, TP53 mutations [9], and IDH1/IDH2 alterations, which are associated with distinct molecular subtypes and clinical outcomes [10]. The gene discussed is IDH2; the disease is glioblastoma.